Login to Your Account

Vicuron Sells Shares, Gets $70.8M For Lead Products

By Karen Pihl-Carey

Friday, October 1, 2004
As it prepares regulatory filings for anidulafungin and dalbavancin, Vicuron Pharmaceuticals Inc. priced a public offering worth $70.8 million in gross proceeds. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription